NovoCure Ltd
No enriched coverage for $NVCR in the last 7 days.
No SEC Form 4 filings for $NVCR in the last 30 days.
NovoCure (NVCR) reported Q2 net revenue of $183.58M and a net loss of $15.66M, and raised its 2026 net revenue outlook to $710M–$725M. The company said it received a CE Mark for Optune Pax in locally advanced pancreatic cancer and expects FDA premarket approval for TTFields in brain metastases from NSCLC.
CSX, Union Pacific (UNP), and Novocure (NVCR) reached 52-week highs after Q2 results beat analyst expectations. CSX reported $3.94B revenue and $0.54 EPS vs $3.8B and $0.52, and analysts raised targets. UNP posted $3.41 adjusted EPS and $6.9B revenue vs $3.23 and higher volumes. NVCR shares rose 28% after Q2 revenue rose 15.6% to $183.6M and adjusted EBITDA turned profitable.
NovoCure (NVCR) reported a narrower-than-expected loss of 13 cents per share and revenue up 16% to $183.584 million, above the $172.437 million estimate. It raised fiscal 2026 revenue guidance to $710 million-$725 million. CE Mark received for Optune Pax in pancreatic cancer. Analysts’ targets range from $17 to $52.
Recent NVCR coverage spans market movers, earnings and regulation.
Guidance upgrade plus new CE approval strengthens the indication-expansion bull case and can support near-term sentiment and estimates.
Improving financials tied to Tumor Treating Fields adoption can sustain upside, but the move may be sensitive to future clinical and commercial traction.
Guidance raise and commercial/patient momentum are positives, but the article notes NVCR shares slid despite the beat, implying investors focused on other concerns like TTFields trial readout.
Analyst valuation reset can drive near-term sentiment and positioning, even as the company’s guidance and EBITDA outlook improved.
Revenue growth and patient expansion are the concrete drivers behind the move, with FDA timing as a forward catalyst.
alphai scores every news story that mentions NVCR with an AI model for sentiment and relevance, and aggregates insider trades from NovoCure Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
NovoCure (NVCR) reported Q2 net revenue of $183.58M and a net loss of $15.66M, and raised its 2026 net revenue outlook to $710M–$725M. The company said it received a CE Mark for Optune Pax in locally advanced pancreatic cancer and expects FDA premarket approval for TTFields in brain metastases from NSCLC.
6 min readCSX, Union Pacific (UNP), and Novocure (NVCR) reached 52-week highs after Q2 results beat analyst expectations. CSX reported $3.94B revenue and $0.54 EPS vs $3.8B and $0.52, and analysts raised targets. UNP posted $3.41 adjusted EPS and $6.9B revenue vs $3.23 and higher volumes. NVCR shares rose 28% after Q2 revenue rose 15.6% to $183.6M and adjusted EBITDA turned profitable.
4 min readNovoCure (NVCR) reported a narrower-than-expected loss of 13 cents per share and revenue up 16% to $183.584 million, above the $172.437 million estimate. It raised fiscal 2026 revenue guidance to $710 million-$725 million. CE Mark received for Optune Pax in pancreatic cancer. Analysts’ targets range from $17 to $52.
5 min readH.C. Wainwright cut its NovoCure Ltd. (NASDAQ:NVCR) price target to $32 from $46 but kept a Buy rating. NVCR trades around $19.99. The firm cited NovoCure’s Q2 2026 revenue of $183.6M and updated 2026 revenue guidance to $710M-$725M, with adjusted EBITDA guidance revised to $0-$15M.
4 min readBiotech stocks rose to 52-week highs on July 22, 2026 after positive updates. Medpace (MEDP) jumped over 77% to $677.90 on Q2 results, with GAAP net income of $121.4M and revenue up 17% to $707M. Novocure (NVCR) gained 28% to $20.55 on Q2 net revenues of $183.6M. Eton (ETON) and Maravai (MRVI) also hit highs; Advanced Biomed (ADVB) rose 36% to $20.87.
3 min readBiotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.
7 min readNovocure (NASDAQ:NVCR) hit a new 52-week high after raising full-year 2026 revenue growth guidance to $710 million to $725 million and expecting positive adjusted EBITDA up to $15 million. Q2 revenues rose 16% to $183.6 million. The company also expects FDA premarket approval in Q4 for TTFields in brain metastases from non-small cell lung cancer.
4 min readNovoCure (Nasdaq: NVCR) reported Q2 2026 revenue of $184 million, up 16% year over year and above analysts’ $172 million estimate. It raised 2026 guidance to $710-725 million from $690-710. Q2 net loss was $15 million ($0.13/share) versus $0.33 expected. Shares rose about 25% as Optune Lua and Optune pancreatic generated $5.4 million and $1.6 million.
6 min readInvesting.com reports U.S. trending stocks with large daily moves. NovoCure (NVCR) rose 23.4% to $19.33 after JPMorgan resumed coverage. WEX (WEX) gained 9.6% after a Q2 EPS beat ($5.35 vs $5.06) and raised guidance. Alphabet fell about 7% on a higher AI spending outlook.
4 min readNovoCure shares rose over 25% after the company reported record Q2 2026 revenue of $184 million, up 16% year over year, and raised full-year guidance. NovoCure posted a Q2 net loss of $16 million, improved from $40 million a year earlier, and expects 2026 revenue of $710 million to $725 million and adjusted EBITDA of $0 to $15 million.
6 min read
